The pathological spread of tau aggregates in Alzheimer's disease relies critically on heparan sulfate proteoglycan (HSPG)-mediated neuronal uptake, but the therapeutic approach can be redirected from sulfatase inhibition to competitive sulfation enhancement. Rather than preserving existing 6-O-sulfation patterns through SULF1/2 inhibition, this strategy leverages the competitive substrate dynamics between different sulfotransferases to create protective HS modification patterns. The 3-O-sulfotransferases, particularly HS3ST3A1 and HS3ST3B1, catalyze the addition of sulfate groups to the 3-OH position of glucosamine residues within HS chains, generating unique 3-O-sulfated domains that exhibit distinct binding specificities compared to 6-O-sulfated motifs. Structural studies reveal that 3-O-sulfated HS domains demonstrate significantly reduced affinity for pathological tau species while maintaining essential physiological interactions with growth factors and extracellular matrix components.

The pathological spread of tau aggregates in Alzheimer's disease relies critically on heparan sulfate proteoglycan (HSPG)-mediated neuronal uptake, but the therapeutic approach can be redirected from sulfatase inhibition to competitive sulfation enhancement. Rather than preserving existing 6-O-sulfation patterns through SULF1/2 inhibition, this strategy leverages the competitive substrate dynamics between different sulfotransferases to create protective HS modification patterns. The 3-O-sulfotransferases, particularly HS3ST3A1 and HS3ST3B1, catalyze the addition of sulfate groups to the 3-OH position of glucosamine residues within HS chains, generating unique 3-O-sulfated domains that exhibit distinct binding specificities compared to 6-O-sulfated motifs. Structural studies reveal that 3-O-sulfated HS domains demonstrate significantly reduced affinity for pathological tau species while maintaining essential physiological interactions with growth factors and extracellular matrix components. The molecular mechanism centers on enhancing HS3ST3A1 activity through targeted upregulation or pharmacological activation, thereby shifting the cellular sulfation equilibrium toward protective 3-O-sulfation patterns. This approach exploits the substrate competition between 6-O- and 3-O-sulfotransferases acting on overlapping glucosamine acceptor sites within HS chains. Enhanced 3-O-sulfation creates a competitive inhibition effect, reducing the availability of glucosamine residues for 6-O-sulfation and consequently diminishing the formation of high-affinity tau binding sites. Additionally, 3-O-sulfated domains may serve as decoy binding sites that sequester tau aggregates without triggering productive endocytic uptake. The therapeutic intervention involves either direct HS3ST3A1 overexpression via gene therapy vectors or small molecule activators that enhance enzyme activity and substrate availability. This mechanism-based approach provides a more targeted intervention that preserves essential HSPG functions while specifically disrupting pathological tau uptake pathways.